KR20170123354A - Medicament comprising glatiramer acetate - Google Patents
Medicament comprising glatiramer acetate Download PDFInfo
- Publication number
- KR20170123354A KR20170123354A KR1020177031069A KR20177031069A KR20170123354A KR 20170123354 A KR20170123354 A KR 20170123354A KR 1020177031069 A KR1020177031069 A KR 1020177031069A KR 20177031069 A KR20177031069 A KR 20177031069A KR 20170123354 A KR20170123354 A KR 20170123354A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- injection
- pharmaceutical composition
- subcutaneous
- months
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract description 129
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract description 126
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract description 126
- 239000003814 drug Substances 0.000 title abstract description 24
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 43
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims description 73
- 238000007920 subcutaneous administration Methods 0.000 claims description 54
- 239000000902 placebo Substances 0.000 claims description 47
- 229940068196 placebo Drugs 0.000 claims description 47
- 238000002347 injection Methods 0.000 claims description 24
- 239000007924 injection Substances 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 20
- 206010022095 Injection Site reaction Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000024780 Urticaria Diseases 0.000 claims description 8
- 230000007803 itching Effects 0.000 claims description 8
- 206010008479 Chest Pain Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 206010022078 Injection site inflammation Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 231100000321 erythema Toxicity 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 229940071643 prefilled syringe Drugs 0.000 claims description 6
- 208000000059 Dyspnea Diseases 0.000 claims description 5
- 206010013975 Dyspnoeas Diseases 0.000 claims description 5
- 206010042674 Swelling Diseases 0.000 claims description 5
- 208000001871 Tachycardia Diseases 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 230000006794 tachycardia Effects 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 206010033557 Palpitations Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 206010008469 Chest discomfort Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 206010016334 Feeling hot Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 206010060800 Hot flush Diseases 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010067142 Immediate post-injection reaction Diseases 0.000 claims description 3
- 206010060708 Induration Diseases 0.000 claims description 3
- 206010022067 Injection site haemorrhage Diseases 0.000 claims description 3
- 206010022086 Injection site pain Diseases 0.000 claims description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 claims description 3
- 206010067868 Skin mass Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 231100000544 menstrual irregularity Toxicity 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010014020 Ear pain Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 206010022081 Injection site mass Diseases 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010030124 Oedema peripheral Diseases 0.000 claims description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 2
- 208000000260 Warts Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000001269 cardiogenic effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 230000024883 vasodilation Effects 0.000 claims description 2
- 206010022093 Injection site pruritus Diseases 0.000 claims 2
- 206010046914 Vaginal infection Diseases 0.000 claims 2
- 201000008100 Vaginitis Diseases 0.000 claims 2
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 abstract description 39
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 230000003902 lesion Effects 0.000 description 50
- 201000006417 multiple sclerosis Diseases 0.000 description 48
- 208000024891 symptom Diseases 0.000 description 24
- 238000002595 magnetic resonance imaging Methods 0.000 description 20
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 19
- 238000012216 screening Methods 0.000 description 19
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 15
- 208000017547 Ectodermal dysplasia-syndactyly syndrome Diseases 0.000 description 15
- 230000008859 change Effects 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 208000024806 Brain atrophy Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000000926 neurological effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 206010006784 Burning sensation Diseases 0.000 description 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010051290 Central nervous system lesion Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022075 Injection site induration Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010072731 White matter lesion Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000007844 axonal damage Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 208000011318 facial edema Diseases 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
본 발명에서는, 재발-완화형 다발성 경화증(relapsing-remitting multiple sclerosis)으로 고통받는 환자 또는 일차 임상적 에피소드(episode)를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 있는 환자를 치료하는데 이용하기 위한, 글라티라머 아세테이트를 포함하는 약제로서, 상기 약제는 40㎎ 용량의 글라티라머 아세테이트를 포함하고, 상기 약제는 매 피하 주사 간에 적어도 1일을 둔 상태에서 매주 3회 피하 주사 요법을 위하여 제조되며, 상기 약제는 5.5 내지 8.5 범위의 pH를 지니는 약제학적 조성물인 것인 약제가 제공된다.In the present invention, there is provided a method for treating a patient suffering from relapsing-remitting multiple sclerosis or a patient suffering from a primary clinical episode and at risk of developing clinically confirmed MS, A medicament comprising glatiramer acetate, wherein the medicament comprises 40 mg dose of glatiramer acetate, the medicament being prepared for subcutaneous injection therapy three times per week for at least one day between each subcutaneous injection, Wherein the medicament is a pharmaceutical composition having a pH in the range of 5.5 to 8.5.
Description
본 출원은 미국 가출원 제61/337,612호(출원일: 2010년 2월 11일) 및 제61/274,687호(출원일: 2009년 8월 20일)의 우선권을 주장하며, 이들 각각의 내용은 본 명세서에 참고로 포함된다.This application claims priority to U.S. Provisional Application No. 61 / 337,612 filed on February 11, 2010 and 61 / 274,687 filed August 20, 2009, each of which is incorporated herein by reference in its entirety It is included as a reference.
본 명세서에서, 다양한 공개물들이 그들의 전문 인용에 의해 참조된다. 이들 공개물들의 개시내용 전부가 본 발명이 속하는 기술 상황을 더욱 충분히 설명하기 위해 본 출원에 참조로 포함된다.In this disclosure, various publications are referenced by their professional citations. The disclosures of these publications are incorporated herein by reference in their entirety to more fully describe the state of the art to which this invention pertains.
다발성 골수종(MS: multiple sclerosis)은 중추신경계(CNS: central nervous system)의 만성적 악화 질환이다. MS는 또한 자가면역질환으로 분류되어 있다. MS 질환 활동성은 뇌의 자기공명영상(MRI), 장애의 축적뿐 아니라, 재발률 및 재발 중증도로 모니터링될 수 있다.Multiple sclerosis (MS) is a chronic aggravating disease of the central nervous system (CNS). MS is also classified as an autoimmune disease. MS disease activity can be monitored by magnetic resonance imaging (MRI) of the brain, accumulation of disorders, as well as recurrence and recurrence severity.
주요한 5가지 형태의 다발성 경화증이 있다:There are five major types of MS:
1) 양성 다발성 경화증(benign multiple sclerosis):1) benign multiple sclerosis:
양성 다발성 경화증은 1 내지 2개의 악화증상들이 초기 발병 후 10 내지 15년간 완전히 회복되고, 장애가 지속되지 않으며, 질환 진행이 없는 것을 특징으로 하는 후향 진단이다. 그러나, 양성 다발성 경화증은 다발성 경화증의 다른 형태들로 진행될 수 있다.Benign MS is a retrospective diagnosis characterized in that 1 to 2 exacerbations are fully recovered 10 to 15 years after the initial onset, the disorder is not sustained, and no disease progression is present. However, positive multiple sclerosis can progress to other forms of multiple sclerosis.
2) 재발-완화형 다발성 경화증(RRMS: relapsing-remitting multiple sclerosis):2) relapsing-remitting multiple sclerosis (RRMS)
RRMS로 고통받는 환자들은 산발성 악화 또는 재발뿐 아니라 완화 기간을 경험한다. 축삭 소실의 병변 및 증거는 RRMS 환자의 MRI 상에서 관찰될 수도 있고 관찰되지 못할 수도 있다.Patients suffering from RRMS experience mitigation periods as well as sporadic deterioration or recurrence. Lesions and evidence of axonal loss may or may not be observed on MRI of patients with RRMS.
3) 2차 진행형 다발성 경화증(SPMS: secondary progressive multiple sclerosis):3) secondary progressive multiple sclerosis (SPMS):
SPMS는 RRMS로부터 진행될 수 있다. SPMS로 고통받는 환자들은 재발을 겪으며, 완화 동안 회복의 정도가 감소하고, RRMS 환자보다 완화의 빈도가 더 적으며, 더욱 현저한 신경학적 결함을 보인다. 뇌량(corpus callosum), 정중선 중심 및 척수의 위축에 대한 표지인 비대 실(enlarged ventricle)을 SPMS 환자의 MRI 상에서 볼 수 있다.The SPMS can proceed from the RRMS. Patients suffering from SPMS experience recurrences, reduced recovery during mitigation, less frequent mitigation than RRMS patients, and more prominent neurological deficits. The enlarged ventricle, which is a marker for corpus callosum, midline midline and atrophy of the spinal cord, can be seen on the MRI of SPMS patients.
4) 1차 진행형 다발성 경화증(PPMS: primary progressive multiple sclerosis):4) Primary progressive multiple sclerosis (PPMS):
PPMS는 뚜렷한 발병(attack) 또는 완화 없이 신경학적 결함이 꾸준하게 증가되는 진행을 특징으로 한다. 대뇌 병변, 광범위 척수 손상 및 축삭 소실의 증거가 PPMS 환자의 MRI 상에서 명백하다.PPMS is characterized by progressive progression of neurological defects without significant attack or mitigation. Evidence of cerebral lesions, extensive spinal cord injury, and axonal loss is evident on the MRI of PPMS patients.
5) 진행-재발형 다발성 경화증(PRMS: progressive relapsing multiple sclerosis):5) Progressive relapsing multiple sclerosis (PRMS)
PRMS는 완화 없이 신경학적 결함이 증가되는 과정을 따라 진행되는 동안 급성 악화 기간을 갖는다. 병변은 PRMS로 고통받는 환자의 MRI 상에서 명백하다(Multiple sclerosis: its diagnosis, symptoms, types and stages, 2003, albany.net/.about .tjc/multiple-sclerosis.html; What are the Types of Multiple Sclerosis?, 2005, <imaginis.com/multiple-sclerosis/types-of-ms. asp? mode=1>).PRMS has an acute exacerbation period during progression of neurological deficit without relief. The lesion is evident on the MRI of patients suffering from PRMS (Multiple sclerosis: its diagnosis, symptoms, types and stages, 2003, albany.net/.about. Tjc / multiple-sclerosis.html; , 2005, <imaginis.com/multiple-sclerosis/types-of-ms. Asp? Mode = 1>).
만성 진행형 다발성 경화증은 일괄적으로 SPMS, PPMS 및 PRMS를 지칭하기 위해 사용되는 용어이다(Types of Multiple Sclerosis (MS), 2005, <themcfox.com/multiple-sclerosis/types-of-ms/types-of-multi-ple-sclerosis. htm>). 재발형의 다발성 경화증은 재발이 중복되는 SPMS, RRMS 및 PRMS이다.Chronic progressive multiple sclerosis is a term used collectively to refer to SPMS, PPMS and PRMS (Types of Multiple Sclerosis (MS), 2005, <themcfox.com/multiple-sclerosis/types-of-ms/types-of -multi-ple-sclerosis. htm >). Multiple sclerosis of recurrent type is SPMS, RRMS, and PRMS with recurrence overlap.
글라티라머 아세테이트(GA: glatiramer acetate)(아미노산 서열이 모두 동일하지는 않은 폴리펩티드들의 혼합물)는 코팍손(Copaxone®)이라는 상품명으로 판매된다. GA는 L-글루탐산, L-알라닌, L-타이로신 및 L-라이신을 각각 0.141, 0.427, 0.095 및 0.338의 평균 몰분율로 함유하는 폴리펩티드의 아세테이트 염을 포함한다. 코팍손의 평균 분자량은 5,000 내지 9,000 달톤이다("Copaxone", Physician's Desk Reference, (2005), Medical Economics Co., Inc., (Montvale, N.J.), 3115). 화학적으로, 글라티라머 아세테이트는 L-알라닌, L-라이신, L-타이로신, 아세테이트(염)를 가지는 L-글루탐산 중합체를 지칭한다.Glatiramer acetate (a mixture of polypeptides whose amino acid sequences are not all identical) is sold under the trade name Copaxone (R). GA comprises acetate salts of polypeptides containing L-glutamic acid, L-alanine, L-tyrosine and L-lysine at an average molar ratio of 0.141, 0.427, 0.095 and 0.338, respectively. The average molecular weight of koaxpans is 5,000 to 9,000 Daltons ("Copaxone", Physician's Desk Reference, (2005), Medical Economics Co., Inc., (Montvale, N.J.), 3115). Chemically, glatiramer acetate refers to L-glutamic acid polymer having L-alanine, L-lysine, L-tyrosine, acetate (salt).
그 구조식은 하기와 같다:The structure is as follows:
(Glu,Ala,Lys,Tyr)x.X CH3COOH(Glu, Ala, Lys, Tyr ) xX CH 3 COOH
(C5H9NO4·C3H7NO2·C6H14N2O2·C9H11NO3) x·x CHO(C 5 H 9 NO 4 .C 3 H 7 NO 2 .C 6 H 14 N 2 O 2 .C 9 H 11 NO 3 ) x x CHO
CAS-147245-92-9CAS-147245-92-9
코팍손("Copaxone", Full Prescribing Information, (February, 2009), FDA Marketing Label)(1일 20㎎ 글라티라머 아세테이트 주사)은, 일차 임상적 에피소드를 경험하고 다발성 경화증과 일치하는 MRI 특징을 갖는 환자를 포함한 재발-완화형 다발성 경화증(RRMS) 환자에 대한 승인된 치료법이다.FDA Marketing Label (20 mg glatiramer acetate injection daily) is an effective and safe treatment for patients with primary clinical episodes and having MRI features consistent with multiple sclerosis It is an approved treatment for patients with relapsing-remitting multiple sclerosis (RRMS), including patients.
GA는 또한 다른 자가면역 질환(미국 특허 공개 2002/0055466 A1(R. Aharoni 등), 염증성 비-자가면역 질환(미국 특허 공개 2005/0014694 A1(V. Wee Yong 등); 및 미국 특허 출원 2002/0077278 A1(공개일: 2002년 6월 20일)(Young 등)) 및 기타 질환(미국 특허 공개 2003/0004099 A1 및 2002/0037848 A1(Eisenbach-Schwartz 등); 미국 특허 6,514,938 B1(등록일: 2003년 2월 4일)(Gad 등); PCT 국제 공개 WO 01/60392(공개일: 2001년 8월 23일)(Gilbert 등); PCT 국제 공개 WO 00/27417(공개일: 2000년 5월 19일)(Aharoni 등); 및 PCT 국제 공개 WO 01/97846(공개일: 2001년 12월 27일)(Moses 등))의 치료에 사용하는 것에 대해서도 개시되어 있다.GA may also be used to treat other autoimmune diseases (U.S. Patent Publication No. 2002/0055466 A1 (R. Aharoni et al.), Inflammatory non-autoimmune diseases (US Patent Publication 2005/0014694 A1 (V. Wee Yong et al. (Eisenbach-Schwartz et al.), U.S. Patent 6,514,938 B1 (Registered Date: 2003) and others (U.S. Patent Application Publication No. 2003/0004099 A1 and 2002/0037848 A1 PCT International Publication No. WO 00/5417 (published on May 19, 2000) (Gad et al.); PCT International Publication No. WO 01/60392 (published on August 23, 2001) ) (Aharoni et al.) And PCT International Publication No. WO 01/97846 (published on December 27, 2001) (Moses et al.).
20㎎/일 피하(s.c.) 투여가 MRI로 측정시 MS 환자에서 증강 병변의 총 수를 감소시키는 것으로 밝혀졌다(G. Comi et al., European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetere on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis, Ann. Neurol. 49:290-297 (2001)).20 mg / day subcutaneous (sc) administration was found to reduce the total number of enhancing lesions in MS patients when measured by MRI (G. Comi et al., European / Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis, Ann. Neurol., 49: 290-297 (2001)).
임상 시험에서 GA에 대해 축적된 안전성 데이터는 약물 제품이 안전하고 잘 용인된다는 것을 보여준다.The safety data accumulated for GA in clinical trials show that the drug product is safe and well tolerated.
일차 임상적 에피소드를 경험하고 다발성 경화증과 일치하는 MRI 특징을 갖는 환자를 포함한 재발형의 다발성 경화증으로부터 고통받는 환자에 대하여 효율적인 낮은 빈도의 GA 투여의 투여 요법이 개시된다.An effective low-dose GA administration regimen is disclosed for patients suffering from recurrent multiple sclerosis, including patients with primary clinical episodes and having MRI features consistent with multiple sclerosis.
본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 재발-완화형 다발성 경화증의 증상을 경감시키는 방법으로서, 인간 환자에게 7일의 기간에 걸쳐서 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사를 매 피하 주사 간에 적어도 1일을 두고 투여함으로써 환자의 증상을 경감시키는 것을 포함하는 방법을 제공한다.The present invention is directed to a method of alleviating the symptoms of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and is determined to have a high risk of developing clinically proven multiple sclerosis, Comprising administering to a human patient a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over a period of 7 days, at least one day between subcutaneous injections, to alleviate the patient ' s symptoms.
본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 GA 치료의 내약성(tolerability)을 증가시키는 방법으로서, 치료적 유효량의 글라티라머 아세테이트를 포함하는 약제학적 조성물의 피하 주사의 빈도를 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회로 감소시키는 것을 포함하는 방법을 제공한다. 또 다른 실시 형태에서, 글라티라머 아세테이트의 치료적 유효량은 40㎎/㎖이다. The present invention relates to a method of increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and is determined to be at high risk of developing clinically confirmed MS, Comprising reducing the frequency of subcutaneous injection of a pharmaceutical composition comprising an effective amount of glatiramer acetate to three times at least one day between each subcutaneous injection over a period of 7 days. In another embodiment, the therapeutically effective amount of glatiramer acetate is 40 mg / ml.
또한, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 재발-완화형 다발성 경화증을 치료하기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제의 투여 패턴은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 둔 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사이다. The present invention also relates to the use of a medicament for the treatment of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the dosage pattern of the medicament is a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over a period of 7 days with at least one day between each subcutaneous injection.
본 발명은 추가로 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서, 재발-완화형 다발성 경화증을 치료하기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제는 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사의 투여 패턴을 위해 제조된다.The present invention further relates to a pharmaceutical composition for the treatment of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the medicament is administered for at least one day between every subcutaneous injection over a period of 7 days with the administration pattern of subcutaneous injection of three therapeutically effective amounts of glatiramer acetate .
또한, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서, GA 치료의 내약성을 증가시키기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제의 투여 패턴은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 둔 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사이다.The present invention also relates to a method for the manufacture of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically confirmed multiple sclerosis Wherein the drug administration pattern is a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over a period of 7 days with at least 1 day between each subcutaneous injection.
본 발명은 추가로 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서, GA 치료의 내약성을 증가시키기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제는 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사의 투여 패턴을 위해 제조된다.The invention further relates to the use of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the medicament is administered for at least one day between every subcutaneous injection over a period of 7 days for administration pattern of subcutaneous injection of three therapeutically effective amounts of glatiramer acetate, do.
또한, 본 발명은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 피하 주사에 의해 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에 있어 재발-완화형 다발성 경화증을 치료하는데 사용하기 위한 글라티라머 아세테이트를 제공한다.The invention also relates to a method of treating a human patient or primary clinical episode suffering from relapsing-remitting multiple sclerosis by three subcutaneous injections at least one day between every subcutaneous injection over a period of 7 days, Provides glatiramer acetate for use in treating relapsing-remitting multiple sclerosis in patients determined to be at increased risk.
또한, 본 발명은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 피하 주사에 의해 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에 있어 GA 치료의 내약성을 증가시키는데 사용하기 위한 글라티라머 아세테이트를 제공한다.The invention also relates to a method of treating a human patient or primary clinical episode suffering from relapsing-remitting multiple sclerosis by three subcutaneous injections at least one day between every subcutaneous injection over a period of 7 days, Provides glatiramer acetate for use in increasing the tolerability of GA treatment in patients determined to be at increased risk.
본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에 있어 재발-완화형 다발성 경화증의 증상을 경감시키는 방법으로서, 인간 환자에게 7일의 기간에 걸쳐서 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사를 매 피하 주사 간에 적어도 1일을 두고 투여함으로써 환자의 증상을 경감시키는 것을 포함하는 방법을 제공한다.The present invention is directed to a method of alleviating the symptoms of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a greater risk of developing clinically proven multiple sclerosis , Comprising administering to a human patient a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over a period of 7 days, at least one day between subcutaneous injections, to alleviate the patient ' s symptoms.
다른 실시형태에서, 매 7일 동안 3회의 주사가 있고, 각 주사 간에는 적어도 1일이 있어야 한다. 추가의 실시형태에 있어서, 가능한 주사 스케쥴은 1일, 3일, 5일; 1일, 3일, 6일; 1일, 3일, 7일; 1일, 4일, 6일; 1일, 4일, 7일; 1일, 5일, 7일; 2일, 4일, 6일; 2일, 4일, 7일; 2일, 5일, 7일; 또는 3일, 5일, 7일을 포함한다.In another embodiment, there are three scans every seven days, with at least one day between each scan. In a further embodiment, the possible scan schedules are 1 day, 3 days, 5 days; 1 day, 3 days, 6 days; 1 day, 3 days, 7 days; 1 day, 4 days, 6 days; 1 day, 4 days, 7 days; 1 day, 5 days, 7 days; 2 days, 4 days, 6 days; 2 days, 4 days, 7 days; 2 days, 5 days, 7 days; Or 3 days, 5 days, 7 days.
일 실시형태에서, 증상을 경감시키는 것은 재발의 빈도를 감소시키는 것을 포함한다.In one embodiment, alleviating the symptoms includes reducing the frequency of recurrence.
또 다른 실시형태에서, 증상을 경감시키는 것은 환자의 뇌에서 Gd-증강 병변의 평균 누적수를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the average cumulative number of Gd-enhancing lesions in the patient's brain.
다른 실시형태에서, 증상을 경감시키는 것은 환자의 뇌에서 새로운 T2 병변의 평균수를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the average number of new T 2 lesions in the patient's brain.
추가의 실시형태에서, 증상을 경감시키는 것은 환자의 T1-가중(weighted) 영상에서 증강 병변의 누적수를 감소시키는 것을 포함한다.In a further embodiment, alleviating the symptoms includes reducing the cumulative number of enhancing lesions in a T 1 -weighted image of the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자의 뇌 위축을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing brain atrophy in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 확인된 재발까지의 시간을 증가시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes increasing the time to recurrence identified in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 확인된 재발의 총수를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the total number of recurrences identified in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 MRI-모니터링된 질환 활동성의 진행을 늦추는 것을 포함한다.In another embodiment, alleviating the symptoms includes slowing the progression of MRI-monitored disease activity in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 T2 병변의 전체 체적을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the overall volume of the T 2 lesion in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자의 증강된 T1 스캔(scan)에서 새로운 저강도(hypointense) 병변의 수를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the number of new low-point (hypointense) lesions in the patient's enhanced T 1 scan.
다른 실시형태에서, 증상을 경감시키는 것은 환자의 증강된 T1 스캔에서 저강도 병변의 총 체적을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the total volume of low intensity lesions in the augmented T 1 scan of the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 EDSS 점수로 측정한 경우 장애의 수준을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the level of the disorder as measured by an EDSS score in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 EDSS 점수의 변화를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing a change in the EDSS score in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 보행 지수(Ambulation Index)의 변화를 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing a change in the Ambulation Index in the subject.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 EuroQoL(EQ5D) 질문서로 측정하는 경우 장애의 수준을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptom includes reducing the level of the disorder when measuring the EuroQoL (EQ5D) question in the patient.
다른 실시형태에서, 증상을 경감시키는 것은 환자에서 일 생산성 및 활동성 장애-일반 건강(WPAI-GH: work productivity and activities impairment - General Health) 질문서로 측정하는 경우 장애의 수준을 감소시키는 것을 포함한다.In another embodiment, alleviating the symptoms includes reducing the level of the disorder when measured in a patient with a daily productivity and activity-impairment (General Health) question (WPAI-GH).
추가의 실시형태에서, 약제학적 조성물은 환자에 의한 자가 투여용 사전 충전된(prefilled) 주사기 내에 있다.In a further embodiment, the pharmaceutical composition is in a prefilled syringe for self-administration by a patient.
다른 실시형태에서, 치료적 유효량의 글라티라머 아세테이트는 40㎎/㎖이다. 추가의 실시형태에서, 치료적 유효량의 글라티라머 아세테이트는 40㎎/0.75㎖이다.In another embodiment, the therapeutically effective amount of glatiramer acetate is 40 mg / ml. In a further embodiment, the therapeutically effective amount of glatiramer acetate is 40 mg / 0.75 ml.
추가의 실시형태에서, 환자는 피하 주사의 개시 전에 글라티라머 아세테이트 치료법을 받은 적이 없다.In a further embodiment, the patient has never been treated with glatiramer acetate before initiation of subcutaneous injection.
일 실시형태에서, 약제학적 조성물은 멸균 용액의 형태이다.In one embodiment, the pharmaceutical composition is in the form of a sterile solution.
다른 실시형태에서, 약제학적 조성물은 만니톨을 추가로 포함한다.In another embodiment, the pharmaceutical composition further comprises mannitol.
또 다른 실시형태에서, 약제학적 조성물은 pH가 5.5 내지 8.5 범위이다.In another embodiment, the pharmaceutical composition has a pH in the range of 5.5 to 8.5.
일 실시형태에서, 약제학적 조성물은 pH가 5.5 내지 7.0 범위이다.In one embodiment, the pharmaceutical composition has a pH in the range of 5.5 to 7.0.
일 실시형태에서, 주사 직후 반응의 빈도 또는 주사 부위 반응의 빈도가 매일 20㎎ 글라티라머 아세테이트의 피하 투여에 비해 감소한다.In one embodiment, the frequency of reactions immediately after injection or the frequency of injection site reactions is reduced relative to subcutaneous administration of 20 mg glatiramer acetate daily.
본 발명은 또한 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에 있어 GA 치료의 내약성을 증가시키는 방법으로서, 치료적 유효량의 글라티라머 아세테이트를 포함하는 약제학적 조성물의 피하 주사의 빈도를 7일의 기간에 걸쳐서 주사 간에 적어도 1일을 두고 3회로 감소시키는 것을 포함하는 방법을 제공한다.The present invention also relates to a method of increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and is determined to be at high risk of developing clinically confirmed MS, Comprising reducing the frequency of subcutaneous injection of a pharmaceutical composition comprising an effective amount of glatiramer acetate to three times at least one day between injections over a period of seven days.
다른 실시형태에서, 재발형의 다발성 경화증으로 고통받는 인간 환자에서 GA 치료의 내약성을 증가시키는 것은 주사 직후 반응의 빈도를 감소시키는 것을 포함한다.In another embodiment, increasing the tolerability of GA treatment in a human patient suffering from recurrent multiple sclerosis involves reducing the frequency of the reaction immediately after injection.
또 다른 실시형태에서, 주사 직후 반응은 심계항진, 열감(feeling hot), 홍조, 열홍조(hot flush), 빈맥, 호흡 곤란, 흉민(chest discomfort), 흉통, 비심인성 흉통(non-cardiac chest), 무력증, 요통(back pain), 박테리아 감염, 오한, 낭종, 안면 부종, 열, 독감 증후군, 감염, 주사 부위 홍반, 주사 부위 출혈, 주사 부위 경결, 주사 부위 염증, 주사 부위 종괴, 주사 부위 통증, 주사 부위 가려움, 주사 부위 두드러기, 주사 부위 부은 자국(welt), 경부통, 통증, 편두통, 실신, 빈맥, 혈관확장, 식욕부진, 설사, 위장염, 위장 장애, 구역, 구토, 반상출혈, 말초 부종, 관절통, 초조, 불안, 혼돈, 족하수, 과다근육긴장증, 신경과민, 눈떨림, 언어 장애, 떨림, 현기증, 기관지염, 호흡곤란, 후두경련, 비염, 홍반, 단순헤르페스, 가려움, 발진, 피부 결절, 발한, 두드러기, 귀통증, 눈 질병, 월경불순, 요절박 또는 질 모닐리아증(vaginal moniliasis)이다.In yet another embodiment, the immediate post-injection reaction may be in the form of palpitation, feeling hot, flushing, hot flush, tachycardia, dyspnea, chest discomfort, chest pain, non-cardiac chest, Infections, Injection site bleeding, Injection site induration, Injection site inflammation, Injection site mass, Injection site pain, Injection site pain, Injection site inflammation, Infections, Back pain, Bacterial infection, Chills, Cysts, Facial edema, In addition, it has been reported that itching, site urticaria, injection warts, pain, migraine, syncope, tachycardia, vasodilation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, Herpes simplex, herpes, itching, rash, skin nodule, sweating, nausea, vomiting, nervousness, nervousness, vertigo, bronchitis, dyspnea, laryngeal cramps, rhinitis, Urticaria, ear pain, eye disease, menstrual irregularities , Vaginal cavity or vaginal moniliasis.
추가의 실시형태에서, 재발형의 다발성 경화증으로 고통받는 인간 환자에서 GA 치료의 내약성을 증가시키는 것은 주사 부위 반응의 빈도를 감소시키는 것을 포함한다.In a further embodiment, increasing the tolerability of GA treatment in a human patient suffering from recurrent multiple sclerosis involves reducing the frequency of injection site reactions.
추가의 실시형태에서, 주사 부위 반응은 주사 부위 바로 근처에서 발생하는 홍반, 출혈, 경결, 염증, 종괴, 통증, 가려움, 두드러기 또는 부은 자국이다.In a further embodiment, the injection site reaction is erythema, hemorrhage, induration, inflammation, mass, pain, itching, urticaria, or swelling that occur near the injection site.
일 실시형태에서, 단일 임상적 발병은 시신경염, 시야혼탁, 복시(diplopia), 비자발적 급속 안구운동, 실명, 균형상실, 떨림, 운동실조증, 현기증, 사지 기능장애, 협응의 결여, 하나 이상의 사지의 쇠약, 변형된 근긴장, 근육 경직, 경련, 자통(tingling), 지각 이상, 작열감, 근육 통증, 안면 통증, 3차 신경통, 찌르는 듯한 예리한 통증, 작열 자통, 말의 둔화, 말의 어눌함, 말의 리듬 변화, 연하곤란, 피로, 방광 문제(급박뇨, 빈뇨, 불완전한 배출 및 요실금을 포함), 장 문제(변비 및 장 조절기능 손실을 포함), 발기 부전, 감퇴된 성흥분, 감각 상실, 열에 대한 민감성, 단기 기억 상실, 집중력 상실 또는 판단이나 논리의 상실의 임상적 에피소드를 포함한다.In one embodiment, a single clinical outbreak is selected from the group consisting of optic neuritis, visual acuity, diplopia, involuntary rapid eye movement, blindness, loss of balance, tremor, ataxia, dizziness, limb dysfunction, lack of coordination, , Tenderling, tingling, tingling sensation, burning sensation, muscle pain, facial pain, trigeminal neuralgia, stinging acute pain, burning sensation, slowing of the horse, irritation of the horse, rhythm change of the horse (Including loss of constipation and bowel control), erectile dysfunction, impaired sexual arousal, sensory loss, sensitivity to heat, difficulty in swallowing, difficulty in swallowing, fatigue, bladder problems (including urgent urine, frequent urination, incomplete discharge and urinary incontinence) Short-term memory loss, loss of concentration, or clinical episodes of loss of judgment or logic.
다른 실시형태에서, 환자는 투여 전에 MRI 스캔에 의해 검출가능한 적어도 1개의 뇌 병변 및 다발성 경화증의 징조(suggestive)를 갖는다.In another embodiment, the patient has at least one brain lesion detectable by MRI scan prior to administration and a suggestive of multiple sclerosis.
또 다른 실시형태에서, 병변은 뇌 조직 염증, 미엘린 수초 손상 또는 축삭 손상과 관련된다.In another embodiment, the lesion is associated with brain tissue inflammation, myelin myelin damage, or axonal damage.
추가의 실시형태에서, 병변은 뇌 MRI 상에서 볼 수 있는 탈수초성 백색질 병변이다.In a further embodiment, the lesion is a dehydrated white matter lesion that is visible on brain MRI.
추가의 실시형태에서, 백색질 병변은 직경이 적어도 3 ㎜이다.In a further embodiment, the whitish lesion has a diameter of at least 3 mm.
또한, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 재발-완화형 다발성 경화증을 치료하기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제의 투여 패턴은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사이다.The present invention also relates to the use of a medicament for the treatment of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the drug administration pattern is a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over at least one day between every subcutaneous injection over a period of 7 days.
추가로, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 재발-완화형 다발성 경화증을 치료하기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제는 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사의 투여 패턴을 위해 제조된다.In addition, the present invention relates to a method for the treatment of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically confirmed multiple sclerosis Wherein the medicament is administered for at least one day between every subcutaneous injection over a period of 7 days with the administration pattern of subcutaneous injection of three therapeutically effective amounts of glatiramer acetate .
또한, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 GA 치료의 내약성을 증가시키기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제의 투여 패턴은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 둔 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사이다.The present invention also relates to the use of a pharmaceutical composition for the manufacture of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the drug administration pattern is a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate over a period of 7 days with at least one day between each subcutaneous injection.
추가로, 본 발명은 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서, GA 치료의 내약성을 증가시키기 위한 약제의 제조에서의 글라티라머 아세테이트의 용도를 제공하며, 여기서, 약제는 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 치료적 유효량의 글라티라머 아세테이트의 피하 주사의 투여 패턴을 위해 제조된다.In addition, the present invention relates to a method of increasing the tolerance of GA therapy in a human patient suffering from relapsing-remitting multiple sclerosis, or in a patient who has experienced a primary clinical episode and has been determined to have a high risk of developing clinically proven multiple sclerosis Wherein the medicament is administered for at least one day between every subcutaneous injection over a period of 7 days for administration of a subcutaneous injection of three therapeutically effective amounts of glatiramer acetate .
본 발명은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 피하 주사에 의해 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 재발-완화형 다발성 경화증을 치료하는데 사용하기 위한 글라티라머 아세테이트를 제공한다.The invention provides a method of treating a human patient or primary clinical episode suffering from relapsing-remitting multiple sclerosis by three subcutaneous injections over at least one day between every subcutaneous injection over a period of 7 days and experiencing a clinically proven multiple sclerosis Provides glatiramer acetate for use in treating relapsing-remitting multiple sclerosis in patients at high risk.
또한, 본 발명은 7일의 기간에 걸쳐서 매 피하 주사 간에 적어도 1일을 두고 3회의 피하 주사에 의해 재발-완화형 다발성 경화증으로 고통받는 인간 환자 또는 일차 임상적 에피소드를 경험하고 임상적 확진 다발성 경화증이 발생할 위험이 큰 것으로 결정된 환자에서 GA 치료의 내약성을 증가시키는데 사용하기 위한 용도를 위한 글라티라머 아세테이트를 제공한다.The invention also relates to a method of treating a human patient or primary clinical episode suffering from relapsing-remitting multiple sclerosis by three subcutaneous injections at least one day between every subcutaneous injection over a period of 7 days, Provides glatiramer acetate for use in increasing the tolerability of GA treatment in patients determined to be at increased risk.
정의Justice
본 명세서에서 사용되는 주사 직후 반응(IRPR)은 주사 직후 발생하는 심계항진, 열감, 홍조, 열홍조, 빈맥, 호흡 곤란, 흉민, 흉통 및 비심인성 흉통과 같은 반응을 말한다. 또한, 반응은 무력증, 요통, 박테리아 감염, 오한, 낭종, 안면 부종, 열, 독감 증후군, 감염, 주사 부위 홍반, 주사 부위 출혈, 주사 부위 경결, 주사 부위 염증, 주사 부위 종괴, 주사 부위 통증, 주사 부위 가려움, 주사 부위 두드러기, 주사 부위 부은 자국, 경부통, 통증, 편두통, 실신, 빈맥, 혈관확장, 식욕부진, 설사, 위장염, 위장 장애, 구역, 구토, 반상출혈, 말초 부종, 관절통, 초조, 불안, 혼돈, 족하수, 과다근육긴장증, 신경과민, 눈떨림, 언어 장애, 떨림, 현기증, 기관지염, 호흡곤란, 후두경련, 비염, 홍반, 단순헤르페스, 가려움, 발진, 피부 결절, 발한, 두드러기, 귀통증, 눈 질병, 월경불순, 요절박 또는 질 모닐리아증을 포함할 수 있다.As used herein, the immediate post-injection response (IRPR) refers to reactions such as palpitations, fever, flushing, fever, tachycardia, dyspnea, chest pain, chest pain, and non-cardiogenic chest pain that occur immediately after injection. In addition, the response may be in the form of incompetence, back pain, bacterial infection, chills, cysts, facial edema, fever, flu syndrome, infection, erythema erythema, injection site hemorrhage, injection site induration, injection site inflammation, Anorexia, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, edema, peripheral edema, joint pain, irritability, anxiety , Herpes zoster, herpes zoster, itching, rash, skin nodule, sweating, urticaria, nasal congestion, chest tightness, Pain, eye disease, menstrual irregularities, epidermal or vaginal atrophy.
본 명세서에서 사용되는 주사 부위 반응(ISR)은 주사 부위 바로 근처에서 발생하는 홍반, 출혈, 경결, 염증, 종괴, 통증, 가려움, 두드러기 및 부은 자국과 같은 반응을 지칭한다.As used herein, injection site reaction (ISR) refers to reactions such as erythema, hemorrhage, induration, inflammation, mass, pain, itching, urticaria and swelling that occur near the injection site.
본 명세서에서 사용되는 "내약성"은 GA 치료와 관련된 불편함의 수준과 관련된다. 내약성은 주사후 반응 및 주사 부위 반응의 빈도 및 중증도와 관련된다. 내약성은 환자가 GA 치료를 따를 수 있는 기간에 영향을 미친다.As used herein, "tolerance" relates to the level of discomfort associated with GA treatment. Tolerance is associated with frequency and severity of postmortem response and injection site response. Tolerance affects the length of time a patient can follow GA treatment.
본 명세서에서 사용되는 Gd-증강 병변이란 용어는 가돌리늄 조영제를 사용하는 조영 연구에서 나타나는 혈액-뇌장벽(blood brain barrier)의 파괴에 기인하는 병변을 지칭한다. 가돌리늄 증가는 Gd-증강 병변이 전형적으로 병변 형성의 6주 이내에 발생하기 때문에 병변의 나이(age)에 관한 정보를 제공한다. As used herein, the term Gd-enhancing lesion refers to a lesion caused by destruction of the blood-brain barrier in an imaging study using a gadolinium contrast agent. Gadolinium increase provides information about the age of the lesion since Gd-enhanced lesions typically occur within 6 weeks of lesion formation.
본 명세서에서 사용되는 T1-가중된 MRI 영상이란 용어는 병변이 가시화될 수 있는 T1 조영을 강조하는 MR-영상을 의미한다. T1-가중된 MRI 영상에서의 비정상적 영역은 "저강도(hypointense)"이며, 검은 점으로 표시된다. 이들 점은 일반적으로 더 오래된 병변들이다.As used herein, the term T 1 -weighted MRI image refers to an MR-image that emphasizes T 1 contrast that a lesion can be visualized. The abnormal region in the T 1 -weighted MRI image is "hypointense" and is indicated by a black dot. These points are generally older lesions.
본 명세서에서 사용되는 T2-가중된 MRI 영상이란 용어는 병변이 가시화될 수 있는 T2 조영을 강조하는 MR-영상을 의미한다. T2 병변은 신규 염증 활동성을 나타낸다.As used herein, the term T 2 -weighted MRI image refers to an MR-image that emphasizes T 2 contrast that a lesion can be visualized. T 2 lesions represent novel inflammatory activity.
본 명세서에서 사용되는 "단위 용량"이란 용어는 필요한 약제 운반체, 예컨대 주사기와 연계된 치료적 유효량의 활성 화합물을 함유하는, 치료될 대상체에 대한 단일 투여 용량으로 적합한 물리적으로 분리된 단위를 말한다.The term "unit dose" as used herein refers to physically discrete units suitable as unitary dosage for a subject to be treated, containing a therapeutically effective amount of the active compound in association with the required pharmaceutical carrier, e.g., a syringe.
본 명세서에서 사용되는 임상적 독립 증후군(CIS: clinically isolated syndrome)이란 1) MS의 단일 임상적 발병 징조 및 2) MS의 적어도 하나의 병변 징조를 의미한다. 일 예로서, 환자는 MRI 스캔으로 검출가능한 적어도 하나의 뇌 병변 및 다발성 경화증의 징조를 갖는다. 추가의 예로서, 병변은 뇌 조직 염증, 미엘린 수초 손상 또는 축삭 손상과 관련된다. 다른 예로서, 병변은 뇌 MRI 상에서 볼 수 있는 탈수초성 백색질 병변이다. 추가의 예에서, 백색질 병변은 직경이 적어도 3 ㎜이다.As used herein, clinically isolated syndrome (CIS) means 1) a single clinical sign of MS and 2) at least one lesion sign of MS. As an example, the patient has at least one brain lesion detectable by an MRI scan and a sign of multiple sclerosis. As a further example, lesions are associated with inflammation of the brain tissue, myelin myelin damage or axonal damage. As another example, lesions are dehydrated white matter lesions that can be seen on brain MRI. In a further example, the whitish lesion has a diameter of at least 3 mm.
"단일 임상적 발병"이란 용어는 "일차 임상적 에피소드", "일차 임상적 발병" 및 "일차 임상적 사건"과 동의어로 사용되며, 이는 예를 들어, 시신경염, 시야혼탁, 복시, 비자발적 급속 안구운동, 실명, 균형상실, 떨림, 운동실조증, 현기증, 사지 기능장애, 협응의 결여, 하나 이상의 사지의 쇠약, 변형된 근긴장, 근육 경직, 경련, 자통, 지각 이상, 작열감, 근육 통증, 안면 통증, 3차 신경통, 찌르는 듯한 예리한 통증, 작열 자통, 말의 둔화, 말의 어눌함, 말의 리듬 변화, 연하곤란, 피로, 방광 문제(급박뇨, 빈뇨, 불완전한 배출 및 요실금을 포함), 장 문제(변비 및 장 조절기능 손실을 포함), 발기 부전, 감퇴된 성흥분, 감각 상실, 열에 대한 민감성, 단기 기억 상실, 집중력 상실 또는 판단이나 논리의 상실의 임상적 에피소드로 나타난다.The term "single clinical onset" is used synonymously with "primary clinical episode", "primary clinical onset", and "primary clinical event", which includes, for example, optic neuritis, visual field opacity, diplopia, Muscle weakness, muscle weakness, muscle stiffness, convulsions, diarrhea, burning sensation, burning sensation, muscle pain, facial pain, (Including urgency, urinary frequency, incomplete discharge and urinary incontinence), intestinal problems (constipation, diarrhea, nausea, vomiting, diarrhea, stomach pain, Impaired sexual arousal, sensory loss, sensitivity to heat, short-term memory loss, loss of concentration, or loss of judgment or logic.
본 명세서에서 사용되는 것으로서, 대상체가 임상적 확진 다발성 골수종(CDMS)과 일치되는 조건을 만족하는지를 결정하기 위해 사용된 문헌[Poser et al., Neurology, March 1983, 13 (3): 227-230]에 의해 정의되는 바와 같은 척도는 하기와 같다:As used herein, Poser et al., Neurology, March 1983, 13 (3): 227-230, which was used to determine if a subject met the condition consistent with clinically proven multiple myeloma (CDMS) Lt; / RTI > are as follows: < RTI ID = 0.0 >
ㆍ 2개의 발병 및 2개의 개별 병변의 임상적 증거, 또는Clinical evidence of 2 outbreaks and 2 individual lesions, or
ㆍ 2개의 발병; 하나의 병변의 임상적 증거 및 다른 개별 병변의 준임상적 증거.2 outbreaks; Clinical evidence of one lesion and subclinical evidence of other individual lesions.
발병(악화, 발적 또는 재발로도 언급됨)은, 객관적 확증이 있거나 없이, 신경학적 기능장애의 증상(들)의 갑작스런 출현 또는 악화로서 임상적으로 정의된다.The onset (also referred to as exacerbation, eruption or recurrence) is clinically defined as the sudden appearance or aggravation of the symptom (s) of neurological dysfunction with or without objective confirmation.
병변의 임상적 증거는 신경학적 검사에 의해 증명할 수 있는 신경학적 기능장애의 징후(sign)로 정의된다. 현재 더이상 존재하지 않더라도 과거에 전문적 검사자에 의해 기록되었다면 비정상적 징후는 임상적 증거를 구성한다.Clinical evidence of lesion is defined as a sign of neurological dysfunction that can be demonstrated by neurological examination. If there is no longer present, abnormal signs constitute clinical evidence if they were recorded by a professional examiner in the past.
병변의 준임상적 증거는 임상적 징후는 보이지 않지만 과거에 증상을 유발하였거나 유발하지 않았을 수 있는 CNS의 병변의 존재에 대한 다양한 시험 및 절차들에 의한 증명으로 정의된다. 이러한 증거는 온욕 테스트, 유발 반응 연구, 신경영상 및 전문적인 신경학적 평가로부터 유도될 수 있다. 이들 테스트는 신경학적 조사의 연장으로 간주되며 실험용의 절차는 아니다.The subclinical evidence of the lesion is defined as evidence of various tests and procedures for the presence of a lesion in the CNS that does not show clinical signs but may or may not have caused symptoms in the past. Such evidence can be derived from warm-blood tests, trigger response studies, neuroimaging and professional neurological evaluation. These tests are considered to be an extension of neurological examinations and are not experimental procedures.
본 명세서에서 사용되는 "글라티라모이드"라는 용어는 분자량 및 서열에 관하여 균일하지 않은 합성 폴리펩티드의 아세테이트 염의 복합 혼합물을 지칭한다.The term " glatiramide "as used herein refers to a complex mixture of acetate salts of synthetic polypeptides that are not homogeneous with respect to molecular weight and sequence.
본 발명은 하기의 실시예 부분에서 예시된다. 이러한 부분은 본 발명의 이해를 돕고자 기술되는 것이며 그 이후에 따르는 청구범위에 기술되는 바와 같은 본 발명을 어떠한 방식으로든 제한하려는 의도가 아니며 제한하려는 것으로 간주되어서는 안된다.The present invention is illustrated in the following Examples section. Such portions are set forth to aid in the understanding of the present invention and are not intended to limit the present invention in any manner whatsoever as set forth in the claims which follow thereafter and should not be construed as limiting.
실험 상세사항Experiment details
실시예Example 1: One:
이중-맹검 설계에서 피하 주사에 의해 주 3회 투여된 40㎎/㎖ 글라티라머 아세테이트(GA) 주사의 위약(placebo)에 대비한 효능, 안전성 및 내약성을 평가하기 위하여, 재발-완화형 다발성 골수종(RRMS) 대상체에서 다국적, 멀티센터(multicenter), 무작위, III 상 평행-그룹 연구를 수행하였다.To assess the efficacy, safety and tolerability of 40 mg / ml glatiramer acetate (GA) injections administered three times weekly by subcutaneous injection in a double-blind design against placebo, the recurrent-mitigating multiple myeloma Multicenter, randomized, and phase III parallel-group studies on RRMS subjects.
방법:Way:
주사를 위해 1주에 3일을 선택하도록 연구를 설계하였다. 매 7일 동안 3회의 주사를 투여하였으며, 각 주사 간에는 적어도 1일이 있어야 한다.The study was designed to select three days a week for injection. Three injections were administered every 7 days and there should be at least one day between each injection.
연구 기간:Research period:
연구 집단:Study group:
RRMS가 있는 대상체Object with RRMS
대상체의Object 수: Number:
1350명의 대상체1350 subjects
연구 목적물(들):Research Object (s):
이중-맹검 연구 설계에서 위약과 비교하여 글라티라머 아세테이트(GA) 주사의 효능, 안전성 및 내약성을 평가하기 위하여, 40㎎/㎖을 주 3회 투여하였다.In a double-blind study design, 40 mg / ml was administered three times a week to assess the efficacy, safety and tolerability of glatiramer acetate (GA) injections compared to placebo.
연구 설계:Research Design:
자격이 있는 대상체를 2:1 비(4O㎎:위약)로 무작위로 선별하여, 하기의 3개 치료 아암 중 하나에 지정하였다:Eligible subjects were randomly selected as 2: 1 ratio (40 mg: placebo) and assigned to one of the following three treatment arms:
1. 주 3회 피하 40㎎ GA(900명의 대상체) 1. Subcutaneously 40 mg GA (900 subjects)
2. 주 3회 매칭 위약(450명의 대상체)2. Matching placebo three times a week (450 subjects)
PC 단계 동안, -1개월(스크리닝), 0개월(기준선), 1개월, 3개월, 6개월, 9개월 및 12개월(PC 단계의 마지막)에서의 총 7회의 예정된 방문에 대해 연구소에서 대상체를 평가하였다.During the PC phase, at the laboratory for a total of seven scheduled visits at -1 months (screening), 0 months (baseline), 1 month, 3 months, 6 months, 9 months and 12 months (at the end of the PC phase) Respectively.
연구를 성공적으로 완료한 대상체에게 오픈 라벨 연장에 참여할 기회를 제공하며, 여기서, 모든 대상체는 40㎎/㎖ GA 용량을 사용한 치료를 계속할 것이다. 이는 40㎎/㎖ GA 용량이 재발 완화형 다발성 골수종(RRMS) 환자의 치료를 위해 시판될 때까지 또는 이러한 투약 요법의 개발이 후원업체에 의해 중단될 때까지 행한다.Provide the subject who has successfully completed the study the opportunity to participate in the open label extension, where all subjects will continue to receive treatment with 40 mg / ml GA dose. This is until the 40 mg / ml GA dose is available for the treatment of patients with relapsed-remitting multiple myeloma (RRMS) or until the development of these dosing regimens is discontinued by the sponsor.
PC 단계의 마지막 방문은 OL 단계의 기준선 방문으로 사용될 것이다. 이러한 단계는 처음 12개월 동안 매 3개월 간격의 계획된 방문, 그 이후에 매 6개월 간격의 계획된 방문을 포함할 것이며, 최종 방문으로 완료될 것이다.The last visit to the PC phase will be used as a baseline visit to the OL phase. These steps will include scheduled visits every three months for the first 12 months, planned visits every six months thereafter, and will be completed with a final visit.
연구 동안, 특정 시간에 하기의 평가를 (치료 지정과 관계없이) 수행한다:During the study, the following evaluation (regardless of treatment designation) is performed at a particular time:
o 감별 완전 혈구 측정(CBC: complete blood count) - PC 단계에서의 모든 계획된 방문 및 그 이후 12개월 간격. 또한, 이러한 테스트를 OL 단계의 최종 방문에 수행할 것이다. o Complete blood count (CBC) - All scheduled visits at the PC level and every 12 months thereafter. This test will also be performed at the final visit of the OL step.
o 혈청 화학물질(전해질, 크레아티닌, 요소 및 간 효소 포함) 및 요검사 - PC 단계에서의 모든 계획된 방문 및 그 이후 12개월 간격. 또한, 이러한 테스트를 OL 단계의 최종 방문에 수행할 것이다.o Serum chemicals (including electrolytes, creatinine, urea and liver enzymes) and urine tests - every scheduled visit at the PC level and every 12 months thereafter. This test will also be performed at the final visit of the OL step.
o 가임기 여성의 혈청 β-hCG를 -1개월(스크리닝), 0개월(기준선), 12개월(PC 단계의 마지막) 및 그 이후 12개월 간격으로 수행한다. 또한, 이러한 테스트를 OL 단계의 최종 방문에 수행할 것이다.o Serum β-hCG in women of childbearing is performed at 1 month (screening), 0 month (baseline), 12 months (at the end of the PC phase), and every 12 months thereafter. This test will also be performed at the final visit of the OL step.
보조 연구:Secondary research:
다발성 경화증 재발에 대하여 허용된 치료는 최대 연속 5일 동안의 1 gr/일의 정맥내 메틸프레드니솔론일 것이다.The allowed treatment for multiple sclerosis recurrence will be 1 g / day of intravenous methylprednisolone for up to 5 consecutive days.
재승인 기준Based on reinstatement
위약-대조 단계 동안, 적어도 3개월 동안 지속되는, MS 재발의 (프로토콜에서 정의된 바와 같은) 확진 진단의 경우, 또는 1.5점 이상의 EDSS의 증가의 경우에, 하기의 행동을 취한다:In the case of a confirmatory diagnosis of MS recurrence (as defined in protocol), or an increase of EDSS of 1.5 or more, which lasts at least 3 months during the placebo-control phase, take the following actions:
연구를 후원업체의 연구원에 의해서뿐 아니라 외부의 독립적인 데이터 모니터링 위원회(DMC)에 의하여 연구 진행 내내 유심히 모니터링하여, 대상체의 복지를 보장한다.Research is monitored not only by the researchers of the sponsoring companies but also by the independent independent data monitoring committee (DMC) throughout the research to guarantee the welfare of the object.
포함/배제:Include / Exclude:
포함 기준:Include by:
o 스크리닝 전 12개월 내에 적어도 1회의 문서로 기록된 재발, 또는 o recurrence recorded at least once within 12 months before screening, or
o 스크리닝 전 24개월 내에 적어도 2회의 문서로 기록된 재발, 또는o recurrence recorded at least twice within 24 months before screening, or
o 스크리닝 전 12개월 내에 수행된 MRI에서 적어도 1개의 문서로 기록된 T1-Gd 증강 병변과 함께 스크리닝 12개월 전과 24개월 전 사이의 1회의 문서로 기록된 재발.o Recurrence recorded in one document between 12 months and 24 months before screening with at least one documented T 1 -Gd enhancement lesion on MRI performed within 12 months before screening.
배제 기준:Exclusion criteria:
경로 및 투여 형태:Routes and dosage forms:
결과 측정:Measuring Results:
일차 결과 측정:Primary result measurement:
이차 결과 측정:Secondary outcome measures:
탐색 종점: 하기의 평가가 탐색 방식으로 제시된다. Search end point: The following evaluation is presented in a search method.
안전성 및 Safety and 내약성Tolerance 결과 측정: Measuring Results:
안전성:safety:
내약성Tolerance ::
통계적 고려사항:Statistical considerations:
연구에 대한 샘플 크기 고려사항은 하기의 가정에 기초한다:The sample size considerations for the study are based on the following assumptions:
게다가, 다음이 또한 샘플 크기 계산에 포함된다:In addition, the following is also included in the sample size calculation:
본페로니(Bonferroni)의 방법에 대한 호크버그(Hochberg)의 스텝-업(step-up) 변형을 사용하여, 다중 치료 아암을 위약과 비교하는 경우, 실험별 I형 오류를 유지하고, IA에 대한 p-값을 오'브리엔-프레밍(O'Brien-Fleming) 알파 소비 함수를 사용하여 계산한다.Using a step-up variant of Hochberg's method for Bonferroni's method, comparing multi-therapy arm to placebo, the patient maintained an I-type error per experiment, The p-value is calculated using the O'Brien-Fleming alpha consumption function.
준-최우(Quasi-Likelihood)(과분산된) 포아송 회귀(SAS® PROC GENMOD)에 사용되는 상기의 근본적인 가정을 설명하는 시뮬레이션 연구로, 총 1350명의 대상체(40㎎ GA 아암에서 900명의 대상체 및 위약 아암에서 450명의 대상체)가 상술된 바와 같은 확인된 재발의 총 수의 유의한 차이를 검출하는 대략 90%의 힘을 제공하는 것으로 드러났다.A simulation study that explains the underlying assumptions used in the Quasi-Likelihood (and disaggregated) SAS® PROC GENMOD. A total of 1350 subjects (900 subjects in a 40 mg GA arm and placebo 450 subjects on the arm) provided approximately 90% power to detect a significant difference in the total number of confirmed recurrences as described above.
연구 기간 동안 확인된 총 재발의 수의 분석은 기준선 조정된 준-최우(과-분산된) 포아송 회귀에 기초한다.Analysis of the total number of recurrences identified during the study is based on baseline-adjusted quasi-maximum (and over-dispersed) Poisson regression.
12개월에 새로운 T2 병변의 수 및 6개월 및 12개월에 취한 T1-가중 영상에서 증강 병변의 누적수의 분석은 기준선 조정된 음이항 회귀(Negative Binomial Regression)에 기초한다.Analysis of the number of new T 2 lesions at 12 months and the cumulative number of enhancement lesions at T 1 -weighted images taken at 6 months and 12 months is based on a baseline-adjusted negative binomial regression.
뇌 위축의 분석은 공변량 분석(ANCOVA: Analysis of Covariance)에 기초할 것이다.Analysis of brain atrophy will be based on Analysis of Covariance (ANCOVA).
결과result
일차 결과 측정:Primary result measurement:
주 3회 피하 40㎎ GA를 사용한 치료는 위약 그룹과 비교하는 경우 대상체 집단 연간 재발률을 30% 이상까지 감소시킨다. 주 3회 피하 40㎎ GA를 사용한 치료는 대상체 집단 연간 재발률을 감소시키는데 있어서 적어도 매일 20㎎의 GA 피하 투여만큼 효과적이다.Treatment with 40 mg subcutaneously subcutaneously 3 weeks reduces the annual recurrence rate of the subject population by more than 30% when compared with the placebo group. Treatment with subcutaneous 40 mg GA three times a week is as effective as at least 20 mg of GA daily subcutaneous dose in reducing the annual recurrence rate of the subject population.
이차 결과 측정:Secondary outcome measures:
탐색 종점:Search Endpoint:
고찰Review
GA 치료법에 대한 중요한 단점은 매일 주사가 필요하다는 것이며, 이는 불편할 수 있다. 더욱이, 모든 임상 시험에서, 주사 부위 반응이 가장 빈번한 유해 반응으로 관찰되었으며, GA를 수여한 대부분의 환자에 의해 보고되었다. 대조된 연구에서, 적어도 1회 이들 반응을 보고한 환자의 비율은 위약 주사(37%)보다 GA를 사용한 치료(70%) 후에 더 높았다. 위약-치료 환자에 비해 GA에서 더욱 빈번히 보고된, 가장 통상적으로 보고된 주사 부위 반응은 홍반, 통증, 종괴, 가려움, 부종, 염증 및 과민증이었다.A major drawback to GA therapy is that it requires daily injections, which can be inconvenient. Moreover, in all clinical studies, injection site reactions were observed as the most frequent adverse reactions and were reported by most GA patients. In the controlled study, the proportion of patients reporting at least one of these reactions was higher after treatment with GA (70%) than with placebo (37%). The most commonly reported injection site reactions reported more frequently in GA than in placebo-treated patients were erythema, pain, mass, itching, swelling, inflammation and hypersensitivity.
그러나, 상기의 단점을 다루기 위한 유력한 방법이 갖는 몇몇 장애 및 제한이 현행의 GA 치료법에 존재한다. 피하 약물 전달은 먼저, 허용가능한 주사 부피에 의해 제한된다. 전형적으로, 1 내지 2㎖ 이하의 용액이 허용된다(Kansara V, Mitra A, Wu Y, Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9(6) :38-42). 두번째로, 생물이용가능성을 감소시키는 주사 부위에서의 약물 분해의 가능성이 존재한다. 세번째로, 약물의 이화학적 특성에 기초하여, 강력한 화합물이 사이질 공간에 국소로 포획될 수 있으며, 이는 추가로 국소화된 자극, 약물의 침전 및 농도-의존적 유해 효과를 야기할 수 있다(Kansara V, Mitra A, Wu Y, Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9(6) :38-42). 마지막으로, 약물의 복잡한 약동학적 거동 때문에, 투여 빈도의 변화를 예측할 수 없고, 경험에 의한 시험을 필요로 한다. 예를 들어, 대조된 임상 시험이 MS의 치료에서 IFNβ-1b의 효능을 나타내었을 지라도, 환자 순응도, 효능 및 내약성은 사용되는 투약 요법에 의해 영향을 받는다. 단지 IFNβ-1b의 용량을 증가시키는 것이 효능을 증가시키는데 충분하지 않고, 투여의 빈도도 또한 증가되어야 한다(Luca Durelli, J Neurol (2003) 250 [Suppl 4]).However, some obstacles and limitations of a viable method for addressing the above drawbacks exist in current GA therapies. Subcutaneous drug delivery is first limited by the allowable injection volume. Typically, no more than 1 to 2 ml of solution is allowed (Kansara V, Mitra A, Wu Y, Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9 (6): 38-42). Second, there is the possibility of drug degradation at the injection site that reduces bioavailability. Third, based on the physicochemical properties of the drug, powerful compounds can be locally trapped in the interstitial space, which can further cause localized irritation, drug precipitation and concentration-dependent deleterious effects (Kansara V , Mitraa, Wu Y, Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9 (6): 38-42). Finally, due to the complex pharmacokinetic behavior of the drug, changes in the frequency of dosing can not be predicted and require testing by experience. For example, although controlled clinical trials have shown efficacy of IFN beta-1b in the treatment of MS, patient compliance, efficacy and tolerability are affected by the dosing regimen used. Only increasing the dose of IFN [beta] -lb is not sufficient to increase efficacy and the frequency of administration should also be increased (Luca Durelli, J Neurol (2003) 250 [Suppl 4]).
따라서, 본 출원은 일차 임상적 에피소드를 경험하고 다발성 골수종과 일치하는 MRI 특징을 갖는 환자를 포함한 재발형의 다발성 골수종으로 고통받는 환자에 대한 효율적인 낮은 빈도의 GA 투여의 투약 요법을 개시한다. 이들 연구에서 투약 요법의 성능에 기초하는 경우, 7일의 기간에 걸친 3회의 피하 주사(매 주사 간에 1일 이상이 있다)의 투여도 또한 임상적으로 분리된 증후군(CIS)을 경험한 환자의 치료에서 작용하는 것으로 예상된다. 이는 PCT 국제 출원 PCT/US2008/013146(국제 공보 WO 2009/070298호 및 또한, 미국 특허 출원 공개 US 2009-0149541 A1 참조)에서 매일 20㎎ 피하 주사가 작용한다는 것을 밝힌 사실에 기초한다.Thus, the present application discloses effective dosing regimens of low-dose GA administration for patients suffering from recurrent multiple myeloma, including patients with primary clinical episodes and having MRI characteristics consistent with multiple myeloma. Based on the performance of the dosing regimen in these studies, the administration of three subcutaneous injections (one day or more between each injection) over a 7-day period was also performed in patients with clinically isolated syndrome (CIS) It is expected to work in therapy. This is based on the fact that 20 mg subcutaneous injections are performed daily in PCT International Application PCT / US2008 / 013146 (International Publication WO 2009/070298 and also US Patent Application Publication US 2009-0149541 A1).
Claims (8)
20mg의 글라티라머 아세테이트의 매일 피하 투여와 비교하여 인간 환자에서 주사 직후 반응 또는 주사 부위 반응의 빈도 감소를 유도함으로써 글라티라머 아세테이트 치료의 내약성을 증가시키며, 재발-완화형 다발성 경화증으로 고통받는 인간 환자에서 재발의 빈도를 감소시키기 위한 약제학적 조성물로서,
상기 약제학적 조성물은 적어도 20mg의 글라티라머 아세테이트의 매일 피하 투여만큼 효과적이고,
상기 약제학적 조성물은 매 7일 동안 각 피하 주사 간에 적어도 48시간의 간격을 가지도록 하면서 1회당 40mg의 글라티라머 아세테이트를 포함하는 약제학적 조성물 1ml을 피하 주사하는 요법에 사용되도록 제조되는, 약제학적 조성물.
In a pre-filled syringe, 40 mg of glatiramer acetate in the form of a 1 ml injection solution was added, and further containing mannitol,
Increase the tolerance of treatment with glatiramer acetate by inducing a reduction in the frequency of reactions or injection site reactions immediately after injection in human patients as compared to daily subcutaneous administration of 20 mg of glatiramer acetate, A pharmaceutical composition for reducing the frequency of recurrence in a patient,
The pharmaceutical composition is as effective as the daily subcutaneous administration of at least 20 mg of glatiramer acetate,
The pharmaceutical composition is prepared for use in a subcutaneous injection of 1 ml of a pharmaceutical composition comprising 40 mg of glatiramer acetate per time, with an interval of at least 48 hours between each subcutaneous injection every 7 days. Composition.
The method according to claim 1, wherein the subcutaneous injection is performed on the first day, the third day, and the fifth day; Day 1, day 3, and day 6; Day 1, day 4, and day 6; Day 2, day 4, and day 6; Day 2, day 4, and day 7; Day 2, day 5, and day 7; Or on day 3, day 5, and day 7 of the pharmaceutical composition.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is effective to reduce the total number of recurrences identified in a human patient.
The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is effective to reduce the recurrence frequency by more than 30% in a human patient compared to a placebo in a human population.
4. The method of claim 1 wherein increasing the tolerability of the glatiramer acetate treatment is achieved by administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula < RTI ID = 0.0 > Composition.
The method of claim 1, wherein the immediate post-injection reaction is selected from the group consisting of palpitations, feeling hot, flushing, hot flush, tachycardia, dyspnea, chest discomfort, chest pain, non-cardiogenic chest pain, Injection site inflammation, Injection site mass, Injection site pain, Injection site itching, Injection site bleeding, Injection site inflammation, Injection site inflammation, Injection site itch, Injection site itching, Urticaria, swelling, warts, pain, migraine, syncope, vasodilation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, epiglottitis, peripheral edema, joint pain, irritability, anxiety, chaos, Herpes, itching, rash, skin nodule, sweating, urticaria, ear pain, eye disease, menstrual irregularities, etc. Herpes simplex, herpes zoster, , Vaginitis or vaginitis (vagi nal moniliasis). < / RTI >
2. The pharmaceutical composition according to claim 1, wherein the injection site reaction is at least one of erythema, hemorrhage, induration, inflammation, mass, pain, itching, urticaria and swelling occurring near the injection site.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US61/274,687 | 2009-08-20 | ||
| US33761210P | 2010-02-11 | 2010-02-11 | |
| US61/337,612 | 2010-02-11 | ||
| PCT/US2010/002283 WO2011022063A1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167006001A Division KR20160038057A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170123354A true KR20170123354A (en) | 2017-11-07 |
Family
ID=43605835
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177031069A KR20170123354A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
| KR1020127007115A KR20120090044A (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
| KR1020167006001A KR20160038057A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
| KR1020147012452A KR20140061559A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127007115A KR20120090044A (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
| KR1020167006001A KR20160038057A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
| KR1020147012452A KR20140061559A (en) | 2009-08-20 | 2010-08-19 | Medicament comprising glatiramer acetate |
Country Status (34)
| Country | Link |
|---|---|
| US (15) | US8399413B2 (en) |
| EP (5) | EP2949335B1 (en) |
| JP (3) | JP6038653B2 (en) |
| KR (4) | KR20170123354A (en) |
| CN (3) | CN102625657A (en) |
| AR (2) | AR077896A1 (en) |
| AT (1) | AT15421U1 (en) |
| AU (1) | AU2010284666B2 (en) |
| BR (1) | BR112012003730A2 (en) |
| CA (2) | CA2760802C (en) |
| CY (2) | CY1114537T1 (en) |
| CZ (2) | CZ30474U1 (en) |
| DE (1) | DE202010018377U1 (en) |
| DK (5) | DK2405749T3 (en) |
| EA (3) | EA032287B1 (en) |
| ES (4) | ES2612001T4 (en) |
| HK (4) | HK1165959A1 (en) |
| HR (4) | HRP20130677T1 (en) |
| HU (2) | HUE031282T2 (en) |
| IL (3) | IL218106A0 (en) |
| LT (3) | LT3199172T (en) |
| ME (2) | ME02662B (en) |
| MX (1) | MX2012002082A (en) |
| NZ (1) | NZ598661A (en) |
| PL (4) | PL2949335T3 (en) |
| PT (4) | PT2405749E (en) |
| RS (2) | RS52885B (en) |
| SG (2) | SG10201405806SA (en) |
| SI (4) | SI2405749T1 (en) |
| SK (1) | SK501352015U1 (en) |
| SM (1) | SMT201700057B (en) |
| TW (3) | TWI477273B (en) |
| UA (1) | UA103699C2 (en) |
| WO (1) | WO2011022063A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (en) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Treatment of Crohn's disease with copolymer 1 and polypeptides |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| PL2949335T3 (en) * | 2009-08-20 | 2017-07-31 | Yeda Research & Development Company, Ltd. | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| MX347871B (en) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate. |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| SG11201505210RA (en) * | 2013-01-04 | 2015-07-30 | Teva Pharma | Characterizing a glatiramer acetate related drug product |
| UY35790A (en) | 2013-10-21 | 2015-05-29 | Teva Pharma | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE |
| CN103641897B (en) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | A kind of method synthesizing acetic acid copaxone |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (en) | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | The preparation method of acetic acid copaxone |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (en) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | Preparation method of glatiramer acetate injection |
| JP7193448B2 (en) | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | Depot system containing glatiramer acetate |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3050086A1 (en) * | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| CN110996983A (en) | 2017-06-26 | 2020-04-10 | 巴斯德研究所 | Treatment to clear HIV reservoirs and reduce viral load |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| KR102519053B1 (en) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | Desolvator system for measuring concentration of hydrochloric acid gas |
| KR102519054B1 (en) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | Hybrid system of napion dryer and desolvator system for measuring concentration of hydrochloric acid gas |
| WO2023062511A1 (en) * | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| ATE55260T1 (en) | 1985-10-11 | 1990-08-15 | Duphar Int Res | AUTOMATIC SYRINGE. |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| ES2527760T3 (en) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Treatment of Crohn's disease with copolymer 1 and polypeptides |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000018794A1 (en) | 1998-09-25 | 2000-04-06 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| NZ517150A (en) | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
| AU780188B2 (en) | 2000-01-20 | 2005-03-03 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| IL150895A0 (en) | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| CA2411536A1 (en) | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| ATE314860T1 (en) | 2000-06-07 | 2006-02-15 | Yeda Res & Dev | USE OF THE COPOLYMER-1 PEPTIDE AND RELATED PEPTIDES AND POLYPEPTIDES AND T CELLS TREATED THEREFROM FOR NEUROPROTECTION AGAINST GLUTAMATE TOXICITY |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| ES2349033T3 (en) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | PROCEDURES FOR MEASURING THE ACTIVITY OF GLATIRAMER ACETATE. |
| AU2003283152A1 (en) | 2002-11-13 | 2004-06-03 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| JP2006507061A (en) | 2002-11-25 | 2006-03-02 | テクファーマ・ライセンシング・アクチェンゲゼルシャフト | Automatic injection device with resettable release safety device |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| MXPA05007711A (en) | 2003-01-21 | 2005-09-30 | Yeda Res & Dev | Cop 1 for treatment of inflammatory bowel diseases. |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| SI1638589T1 (en) | 2003-05-14 | 2014-07-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| CA2541445A1 (en) | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Nanoparticles for drug delivery |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| UA89226C2 (en) * | 2004-03-25 | 2010-01-11 | Янссен Фармацевтика Н.В. | Imidazole compounds |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| WO2005112972A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| SG153871A1 (en) * | 2004-06-25 | 2009-07-29 | Id Biomedical Corp Quebec | Compositions and methods for treating neurological disorders |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| PL1797109T3 (en) | 2004-09-09 | 2016-11-30 | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof | |
| PT2361924E (en) | 2004-09-09 | 2014-03-13 | Teva Pharma | Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
| JP5297653B2 (en) | 2004-10-29 | 2013-09-25 | サンド・アクチエンゲゼルシヤフト | Manufacturing method of glatiramer |
| RU2419638C2 (en) | 2005-02-02 | 2011-05-27 | Тева Фармасьютикал Индастриз, Лтд. | Method of preparing polypepdite mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| SI1848415T1 (en) | 2005-02-17 | 2013-08-30 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| WO2008005315A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Biotechnology Ltd. | Automatic injection device |
| DE602007003848D1 (en) | 2006-07-05 | 2010-01-28 | Momenta Pharmaceuticals Inc | IMPROVED METHOD FOR PREPARING COPOLYMER-1 |
| JP2010540634A (en) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Method for treating autoimmune neurological diseases using cyclophosphamide |
| AU2008330093A1 (en) | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| DK2275086T3 (en) | 2009-07-15 | 2012-07-09 | Teva Pharma | Reduced volume formulation of glatiramer acetate and methods of administration thereof |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| PL2949335T3 (en) * | 2009-08-20 | 2017-07-31 | Yeda Research & Development Company, Ltd. | Low frequency glatiramer acetate therapy |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| MX347871B (en) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate. |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| SG11201505210RA (en) | 2013-01-04 | 2015-07-30 | Teva Pharma | Characterizing a glatiramer acetate related drug product |
| MX2015012156A (en) | 2013-03-12 | 2015-11-30 | Teva Pharma | Rituximab induction therapy followed by glatiramer acetate therapy. |
-
2010
- 2010-08-19 PL PL15171065T patent/PL2949335T3/en unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/en unknown
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/en active Active
- 2010-08-19 PT PT108102823T patent/PT2405749E/en unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/en active Active
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/en not_active Ceased
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/en unknown
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/en active Active
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/en unknown
- 2010-08-19 NZ NZ598661A patent/NZ598661A/en unknown
- 2010-08-19 SI SI201030270T patent/SI2405749T1/en unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/en unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/en not_active Application Discontinuation
- 2010-08-19 PL PL17157735T patent/PL3199172T3/en unknown
- 2010-08-19 SI SI201031375A patent/SI2949335T1/en unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 US US12/806,684 patent/US8399413B2/en active Active
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/en active Pending
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/en active Active
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en active Active
- 2010-08-19 SI SI201031719T patent/SI2630962T1/en unknown
- 2010-08-19 SI SI201031740T patent/SI3199172T1/en unknown
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/en unknown
- 2010-08-19 EA EA201270292A patent/EA019998B9/en not_active IP Right Cessation
- 2010-08-19 ES ES10810282T patent/ES2424692T3/en active Active
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/en active
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/en unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/en not_active IP Right Cessation
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en active Application Filing
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/en not_active IP Right Cessation
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/en active IP Right Grant
- 2010-08-19 PL PL13166080T patent/PL2630962T3/en unknown
- 2010-08-19 PT PT17157735T patent/PT3199172T/en unknown
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/en unknown
- 2010-08-19 RS RS20170053A patent/RS55607B1/en unknown
- 2010-08-19 PT PT131660805T patent/PT2630962T/en unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/en not_active Application Discontinuation
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/en unknown
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en active Active
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/en active Pending
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 EA EA201400394A patent/EA032283B1/en unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en active Active
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/en active Pending
- 2010-08-19 PT PT151710654T patent/PT2949335T/en unknown
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/en unknown
- 2010-08-19 PL PL10810282T patent/PL2405749T3/en unknown
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/en active Search and Examination
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/en not_active Application Discontinuation
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/en not_active Application Discontinuation
- 2010-08-19 UA UAA201203259A patent/UA103699C2/en unknown
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/en not_active IP Right Cessation
- 2010-08-20 TW TW099128023A patent/TWI477273B/en active
- 2010-08-20 AR ARP100103062A patent/AR077896A1/en not_active Application Discontinuation
- 2010-08-20 TW TW103138861A patent/TWI643614B/en not_active IP Right Cessation
- 2010-08-20 TW TW106100768A patent/TW201733575A/en unknown
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en active Active
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
- 2012-07-12 HK HK12106867.3A patent/HK1165959A1/en not_active IP Right Cessation
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-17 HR HRP20130677AT patent/HRP20130677T1/en unknown
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/en unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/en not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/en active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/en unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/en not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-06-01 HK HK16106219.4A patent/HK1218250A1/en not_active IP Right Cessation
- 2016-12-01 HK HK16113727A patent/HK1225310A1/en unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/en unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/en unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/en unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/en not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/en unknown
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/en unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9155776B2 (en) | Low frequency glatiramer acetate therapy | |
| AU2013203367B2 (en) | Low frequency glatiramer acetate therapy | |
| AU2016100455B4 (en) | Low frequency glatiramer acetate therapy | |
| AU2015101564A4 (en) | Low frequency glatiramer acetate therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019101003697; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191107 Effective date: 20200428 |